



The Role of HPV in Oropharyngeal Cancer: Diagnosis and Management

Ruiko Kuniyasu*

Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA

Introduction:

HPV, particularly subtype 16, has been identified as a major etiological factor in oropharyngeal cancer. This subtype of HPV has distinct characteristics and is more commonly associated with oropharyngeal cancers compared to other head and neck cancers [1].

The rise in HPV-related oropharyngeal cancers, notably among younger individuals, has led to a shift in the demographics of those affected by this disease. This change in incidence has sparked a need for different diagnostic and management approaches [2].

The detection of HPV in oropharyngeal cancer poses diagnostic challenges. Newer diagnostic techniques, including molecular assays and HPV-specific biomarkers, have been developed to identify HPV-related cancers accurately [3].

HPV status in oropharyngeal cancer holds significant prognostic value. Patients with HPV-positive tumors generally exhibit better treatment responses and survival rates compared to those with HPV-negative tumors [4].

The presence of HPV in oropharyngeal cancer influences treatment decisions. Patients with HPV-positive tumors often respond more favorably to treatment modalities like radiation therapy and chemotherapy, leading to better outcomes [5].

The distinct molecular characteristics of HPV-related oropharyngeal cancers have paved the way for targeted therapies. These treatments specifically target HPV-related pathways, offering potentially more effective and less toxic options [6].

Given the link between HPV and oropharyngeal cancer, preventive strategies like HPV vaccination have gained prominence. Vaccination efforts aim to

reduce HPV infections and subsequently lower the incidence of associated cancers [7].

Understanding the role of HPV in oropharyngeal cancer is crucial in patient counseling and education. Patients benefit from being informed about the implications of HPV status on their diagnosis, treatment, and prognosis [8].

Post-treatment surveillance strategies take into account HPV status. Regular follow-ups and surveillance protocols are tailored based on HPV status to monitor for potential recurrence or metastasis [9].

Ongoing research focuses on further elucidating the intricacies of HPV-related oropharyngeal cancers. This continuous exploration aims to refine diagnostic methods, improve treatment options, and enhance overall patient care [10].

Conclusion

The recognition of HPV's role in oropharyngeal cancer has revolutionized the diagnosis and management of this disease. From improved diagnostic techniques to tailored treatment approaches and preventive strategies, the understanding of HPV's involvement has opened doors for more targeted and effective interventions. Continuing research endeavors and a comprehensive understanding of the interplay between HPV and oropharyngeal cancer are instrumental in advancing diagnostic precision, optimizing treatment outcomes, and ultimately improving the lives of individuals affected by this form of cancer.

References

1. Tumban E. A current update on human papillomavirus-associated head and neck cancers. *Viruses*. 2019;11(10):922.

*Corresponding author: Kuniyasu R, Department of Epidemiology, Johns Hopkins Bloomberg School of Public Health, USA. E-mail: kuniyasuruiko@jhmi.edu

Received: 29-Dec-2023, Manuscript No. jorl-23-123745; Editor assigned: 01-Jan-2024, Pre QC No. jorl-23-123745 (PQ); Reviewed: 15-Jan-2024, QC No. jorl-23-123745; Revised: 20-Jan-2024, Manuscript No. jorl-23-123745 (R); Published: 27-Jan-2024, DOI: 10.35841/2250-0359.14.1.366

2. Cerar J, Bryant KB, Shoemaker SE, et al . HPV-Positive Oropharyngeal Cancer: The nurse's role in patient management of treatment-related sequelae. *Clinical Journal of Oncology Nursing*. 2020;24(2).
3. Ducatman BS. The role of human papillomavirus in oropharyngeal squamous cell carcinoma. *Archives of pathology & laboratory medicine*. 2018;142(6):715-8.
4. Hinni ML, Nagel T, Howard B. Oropharyngeal cancer treatment: the role of transoral surgery. *Current Opinion in Otolaryngology & Head and Neck Surgery*. 2015;23(2):132-8.
5. Ridge JA. Surgery in the HPV era: the role of robotics and microsurgical techniques. *American Society of Clinical Oncology Educational Book*. 2014;34(1):154-9.
6. Elrefaey S, Massaro MA, Chiocca S, et al. HPV in oropharyngeal cancer: the basics to know in clinical practice. *Acta Otorhinolaryngologica Italica*. 2014;34(5):299.
7. Fung N, Faraji F, Kang H, et al. The role of human papillomavirus on the prognosis and treatment of oropharyngeal carcinoma. *Cancer and Metastasis Reviews*. 2017;36:449-61.
8. Resteghini C, Perrone F, Miceli R, et al. Prognostic role of PIK3CA and TP53 in human papillomavirus–negative oropharyngeal cancers. *Tumori Journal*. 2018;104(3):213-20.
9. Nguy S, Oh C, Karp JM, et al. Radiotherapy in Metastatic Oropharyngeal Cancer. *The Laryngoscope*. 2021;131(6):E1847-53.
10. Ghazal Asswad R, Alvi S, Davies K, et al. The role of multidisciplinary decision making in oropharyngeal cancer: do we follow guidelines and are treatment decisions being implemented?. *European Archives of Oto-Rhino-Laryngology*. 2020;277:947-52.